**Description**

**A HYPOTHERMIC, HYPOTENSIVE AND HYPOLIPIDEMIC COMPOSITION**

**Technical Field**

The invention relates to a hypothermic, hypotensive and hypolipidemic composition.

**State of the Art**

Hypothermia is the disorder occurring when the normal body temperature, which is 37 °C, drops below 35 °C.

Hypotension means the low blood pressure in which case the systolic blood pressure is less than 90 mmHg.

Although the lower limits of the normal blood pressure vary from one individual to another, these are accepted to be systolic 90 and diastolic 60 mmHg. The cause of the hypotension is the increased activity of the parasympathetic nervous system or other disorders and it generally exhibits the syndrome of weakness. Hypotension also occurs in case of imbalance and deficiency of the sodium and the ions in the body. Dizziness, tinnitus and fainting are the frequently observed complaints in case of hypotension.

Lipid lowering drugs are the various kinds of medicaments used in the treatment of high lipid levels in the blood. They are also called hypolipidemic drugs or antihyperlipidemic drugs. Lipid lowering drugs may be divided into several classes. They exhibit differences in terms of side effects and the effects on the cholesterol profile. Some drugs reduce the LDL cholesterol known as “bad cholesterol”, while some others increase the HDL cholesterol, “good cholesterol”. In clinical use, in order to determine what drug a patient is to take, the cholesterol level, cardiovascular risk condition and liver and kidney function of the patient are examined and these are assessed along with the risks and benefits of the drug. In the United States of America, the treatment guide based on the evidence found in National Cholesterol Education Program Adult Treatment Panel III is used for this purpose.

* [Statin](http://tr.wikipedia.org/wiki/Statin)s are very effective in lowering LDL cholesterol, which is shown to be most directly associated with the heart diseases. Statin derivatives have been shown to lower LDL cholesterol by 18%-55%.
* [Fibrat](http://tr.wikipedia.org/wiki/Fibrat)es are used in the conditions where triglycerides are elevated. Triglycerides are lowered by 20% to 50% as a result of using these drugs. HDL cholesterol level also increases, but LDL cholesterol is lowered very slightly and it may even become elevated.
* Like fibrates, nicotinic acid also serves to lower the triglycerides. Its beneficial effects are observed on both LDL cholesterol and HDL cholesterol levels.
* Bile acid binding resins are effective especially in lowering LDL cholesterol. They lower LDL cholesterol by 15-30% and elevate HDL cholesterol. They do not have significant effect on triglycerides.
* Phyto[sterol](http://tr.wikipedia.org/wiki/Fitosterol) (cholesterol absorption inhibitors)
* [CETP inhibitors](http://tr.wikipedia.org/w/index.php?title=CETP_inhibit%C3%B6rleri&action=edit&redlink=1)
* [Squalene synthase inhibitors](http://tr.wikipedia.org/w/index.php?title=Skualen_sentaz_inhibit%C3%B6rleri&action=edit&redlink=1)

The invention no. WO 1999/035135 entitled "Hypolipidemic benzothiazepine compounds" is concerned with novel hypolipidemic compounds of formula (I), wherein R1 is H or methyl, and salts, solvates or physiologically functional derivatives thereof; with processes and novel intermediates for their preparation, pharmaceutical compositions containing them; and with their use in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions and associated diseases, such as atherosclerosis.

The invention no. EP1392319B1 entitled "Hypotensive lipid (prostaglandin) and timolol compositions and methods of using the same" provides new compositions for and methods of treating ocular hypertension and provides for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component. The present compositions and methods are relatively straightforward, can be easily produced, for example, using conventional manufacturing techniques, and can be easily and conveniently practiced, for example, using application or administration techniques or methodologies which are substantially similar to those employed with prior compositions used to treat ocular hypertension.

The invention no. EP1761495B1 entitled "Piperidinyl prostaglandin analogs as ocular hypotensive agents" discloses a compound comprising (I) or a pharmaceutically acceptable salt or a prodrug thereof. Y and R are described in detail herein. A compound having an ω chain comprising (II) or a derivative thereof, or a pharmaceutically acceptable salt or a prodrug thereof, is disclosed. Derivatives, salts and prodrugs are identified and described in detail. Methods of treating certain conditions or diseases, and compositions and medicaments related thereto are also contemplated.

As a result, the presence of the need for a hypothermic, hypotensive and hypolipidemic composition and the inadequacy of the existing solutions have made it necessary to perform an improvement in the relevant art.

**Object of the Invention**

In order to eliminate the disadvantages of the state of the art, an object of the invention is to support the production of star (steroidogenic acute regulatory protein).

Another object of the invention is to suppress acetyl koA enzyme.

Another object of the invention is to support the nitric oxide release by increasing the production of acetylcholine.

Another object of the invention is to lower the total cholesterol level and balance HDL:LDL ratio.

Another object of the invention is to suppress the fat absorption in the intestines.

Another object of the invention is to provide hypothermic effect by reducing the level of 5-hydroxytryptamine.

Another object of the invention is to provide hypothermia by exhibiting antagonistic effect on hypothalamic serotonin receptors.

Another object of the invention is to lower the blood pressure and exhibit anti-sympathomimetic effect owing to the partial beta-receptor antagonistic property.

Another object of the invention is to prevent atherosclerosis owing to the nitric oxide increase and lower the blood pressure by supporting the circulation.

In order to achieve the aforesaid advantages, the invention is a hypothermic, hypotensive and hypolipidemic composition, said composition being obtained by the components selected from the group comprising 4-0-allylmagnolol and 7-hydroxypuerarin that are used individually or in combinations.

The structural and characteristic features and all the advantages of the invention will become more clearly understood from the detailed description provided below and therefore, the evaluation must be made taking this detailed description into consideration.

**Detailed Description of the Invention**

The invention is a hypothermic, hypotensive and hypolipidemic composition. The composition according to the invention contains 4-0-allylmagnolol and 7-hydroxypuerarin.

4-0-allylmagnolol, an ingredient of said composition, supports the production of star (steroidogenic acute regulatory protein). It suppresses acetyl koA enzyme. 4-0-allylmagnolol also supports the nitric oxide release by increasing the production of acetylcholine. 4-0-allylmagnolol also lowers the total cholesterol level and balances HDL:LDL ratio.

7-hydroxypuerarin suppresses the fat absorption in the intestines. 4-0-allylmagnolol provides hypothermic effect by reducing the level of 5-hydroxytryptamine. 7-hydroxypuerarin also provides hypothermia by exhibiting antagonistic effect on hypothalamic serotonin receptors. 7-hydroxypuerarin also lowers the blood pressure and exhibits anti-sympathomimetic effect owing to the partial beta-receptor antagonistic property. 7-hydroxypuerarin also prevents atherosclerosis and supports the circulation owing to the nitric oxide increase and also lowers the blood pressure for the same reason.

Said formulation is obtained by a mixture of the aforesaid components according to the following ratios by weight:

95-5% 4-0-allylmagnolol,

5-95% 7-hydroxypuerarin.

The composition is obtained from the aforesaid components selected from the aforesaid group and used according to the mentioned weight ratio ranges individually or in combinations.

Said invention also encompasses the hypothermic, hypotensive and hypolipidemic use of said composition and the manufacture thereof for this purpose.

**CLAIMS**

1. A hypothermic, hypotensive and hypolipidemic composition, said composition being obtained by the components selected from the group comprising 4-0-allylmagnolol and 7-hydroxypuerarin that are used individually or in combinations.
2. A composition according to Claim 1 characterized in that it comprises 95-5% by weight 4-0-allylmagnolol.
3. A composition according to Claim 1 characterized in that it comprises 5-95% by weight 7-hydroxypuerarin.
4. Use of the components according to Claims 1 to 3 obtained individually or in combinations from the group consisting of 4-0-allylmagnolol and 7-hydroxypuerarin for the manufacture of a hypothermic, hypotensive and hypolipidemic composition.

**ABSTRACT**

**A HYPOTHERMIC, HYPOTENSIVE AND HYPOLIPIDEMIC COMPOSITION**

The invention relates to a hypothermic, hypotensive and hypolipidemic composition.

No figure.